Endocrine Abstracts

Contents

• 4th Theranostics World Congress 2016
• • Oral Speaker Communications
  • Spotlight on Neuroendocrine tumours
  • • Integrating cancer genomics with imaging

      ea0047oc1
    • Production of Ga-68 radiotracers under GMP and regulatory aspects - a German perspective

      ea0047oc2
    • Optimised production of 64Cu-SARTATE for a phase 1 clinical trial

      ea0047oc3
    • 68Ga, 64Cu labelling and affinity study of NODAGANOC, a NODAGA conjugated somatostatin analogue

      ea0047oc4
    • Influence of the radiopharmaceutical affinity and peptide content on the pharmacokinetics: [68Ga]Ga-DOTATOC and [68Ga]Ga-DOTATATE

      ea0047oc5
    • DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy patients with personalised high activities

      ea0047oc6
    • Two Decades of THERANOSTICS in Neuroendocrine Tumors - Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT)

      ea0047oc7
    • NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

      ea0047oc8
    • Clinical Perspective: The 'difficult development situation': how to approach and overcome challenges from a regulatory perspective

      ea0047oc9
    • The Cruel Wait for PRRT

      ea0047oc10
    • The challenges of waiting for RCTs vs treating patient's now

      ea0047oc11
    • PET/CT based dosimetry for 90Y-DOTATOC treatment of neuroendocrine cancer

      ea0047oc12
    • Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: a simulation study

      ea0047oc13
    • 68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a head-to-head comparison with DOTATOC and FDG PET/CT

      ea0047oc14
    • Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large series of paragangliomas

      ea0047oc15
    • Benefits and challenges of translating pre-clinical studies into clinical practice

      ea0047oc16
    • Dosimetry in 177Lu treatment: what we know and what we do not know

      ea0047oc17
  • Spotlight on Prostate Cancer
  • • The Holy Grail: individualised dosimetry for radionuclide therapy

      ea0047oc18
    • The history of PSMA and future directions

      ea0047oc19
    • Evolving evidence of PSMA PET/CT

      ea0047oc20
    • Should PSMA PET/CT replace conventional imaging?

      ea0047oc21
    • PET/MRI: better AND worse than PET/CT for PSMA PET imaging

      ea0047oc22
    • Imaging the expression of gastrin releasing peptide receptors in prostate cancer using Ga-68 labeled antagonists

      ea0047oc23
    • How to get away with PET+MRI

      ea0047oc24
    • Re-assessing gallium-67 as a therapeutic radionuclide

      ea0047oc25
    • 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment

      ea0047oc26
    • Initial experience with aggressive treatment of metastastic prostate cancer using 3 cycles of 7.4 GBq [177Lu]-PSMA every 4 weeks

      ea0047oc27
    • Theranostic in early detection of recurring prostate cancer: 64CuCl2

      ea0047oc28
    • A short history of transforming the diagnostic tracer PSMA-11 into the theranostic variant PSMA-617

      ea0047oc29
    • Beyond wizardry: creating high level evidence for PSMA PET Imaging and Theranostics

      ea0047oc30
    • First in-man study of 68Ga-THP-PSMA PET in patients with primary prostate cancer: initial results

      ea0047oc31
    • Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

      ea0047oc32
    • Molecular imaging with 64Cu-PSMA PET/CT in Theranostics of prostate cancer

      ea0047oc33
    • Radiolabelling of DOTAMZOL with 68Ga and 44Sc for clinical application

      ea0047oc34
  • Innovative Theranostics
  • • Kit-based Ga-68 PET imaging

      ea0047oc35
    • Bone seeking bisphosphonate therapy

      ea0047oc36
    • The development of copper-based imaging and therapeutics agents

      ea0047oc37
    • How I do it; delivering outpatient theranostics

      ea0047oc38
    • The success and failure of radioimmunotherapy for lymphoma

      ea0047oc39
    • PSMA in breast cancer

      ea0047oc40
    • Theranostics for the invasive cancer phenotype: uPAR targeted theranostics

      ea0047oc41
    • Optimizing theranostics through pretargeting approaches

      ea0047oc42
    • Initial South African experience on 68Ga/213Bi radiolabeling for prospective theranostics

      ea0047oc43
    • Critical aspects of radiochemical purity determination of 68Ga-BCA-peptides and behavioral features of different 68Ga species

      ea0047oc44
    • Glioma tumors grade II/III - local alpha emiters targeted therapy with 213Bi-DOTA-substance P

      ea0047oc45
    • Spatially informed dose deposition of Auger electron-emitting radionuclides at a cell nucleus scale

      ea0047oc46
    • Noninvasive imaging of multiple Myeloma with 68Ga-DOTA-PEG4-LLP2A via targeting VLA-4

      ea0047oc47
    • Theranostics at its best: clinical breast cancer imaging and quantification targeting HER2 receptors

      ea0047oc48
    • Production of 68Ga in a mid-energy cyclotron: the solution is in the target

      ea0047oc49
    • Radiolabel results from high specific activity e-LINAC produced 67Cu

      ea0047oc50
    • Ga-68 research status in Asia

      ea0047oc51